Logo: to the web site of Uppsala University

uu.sePublikasjoner fra Uppsala universitet
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Cancerimmunterapi.ORCID-id: 0009-0000-0563-3243
Stockholm Univ, Dept Biochem & Biophys, Sci Life Lab, Stockholm, Stockholm Count, Sweden..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Cancerimmunterapi.ORCID-id: 0000-0003-0901-5252
Stockholm Univ, Dept Biochem & Biophys, Sci Life Lab, Stockholm, Stockholm Count, Sweden..
Vise andre og tillknytning
2025 (engelsk)Inngår i: Journal for ImmunoTherapy of Cancer, E-ISSN 2051-1426, Vol. 13, nr 8, artikkel-id e012089Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background T-cell activation and clonal expansion are essential to effective immunotherapy responses in non-small cell lung cancer (NSCLC). The distribution of T-cell clones may offer insights into immunogenic mechanisms and imply potential prognostic and predictive information.

Methods We analyzed alpha/beta T-cell receptor (TCR) clonality using RNA-sequencing of bulk frozen tumor tissue from 182 patients with NSCLC. The data was integrated with molecular and clinical characteristics, extensive in situ imaging, and spatial sequencing of the tumor immune microenvironment. TCR clonality was also determined in an independent cohort of nine patients with immune checkpoint-treated NSCLC.

Results TCR clonality (Gini index) patterns ranged from high T-cell clone diversity with high evenness (low Gini index) to clonal dominance with low evenness (high Gini index). Generally, TCR clonality in cancer was lower than in matched normal lung parenchyma distant from the tumor (p=0.021). The TCR clonality distribution between adenocarcinoma and squamous cell carcinoma was similar; however, smokers showed a higher Gini index. While in the operated patient with NSCLC cohort, TCR clonality was not prognostic, in an immune checkpoint inhibitor-treated cohort, high TCR clonality was associated with better therapy response (p=0.016) and prolonged survival (p=0.003, median survival 13.8 vs 2.9 months). On the genomic level, a higher Gini index correlated strongly with a lower frequency of epidermal growth factor receptor (EGFR) and adenomatous polypsis coli (APC) gene mutations, but a higher frequency of P53 mutations, and a higher tumor mutation burden. In-depth characterization of the tumor tissue revealed that high TCR clonality was associated with an activated, inflamed tumor phenotype (PRF1, GZMA, GZMB, INFG) with exhaustion signatures (LAG3, TIGIT, IDO1, PD-1, PD-L1). Correspondingly, PD-1+, CD3+, CD8A+, CD163+, and CD138+immune cells infiltrated cancer tissue with high TCR clonality. In situ sequencing recovered single dominant T-cell clones within the patient tumor tissue, which were predominantly of the CD8 subtype and localized closer to tumor cells.

Conclusion Our robust analysis pipeline characterized diverse TCR repertoires linked to distinct genotypes and immunologic tumor phenotypes. The spatial clustering of expanded T-cell clones and their association with immunological activation underscores a functional, clinically relevant immune response, particularly in patients with NSCLC treated with checkpoint inhibitors.

sted, utgiver, år, opplag, sider
BMJ Publishing Group Ltd, 2025. Vol. 13, nr 8, artikkel-id e012089
Emneord [en]
T cell Receptor - TCR, Immune Checkpoint Inhibitor, T cell, Lung Cancer, Clonality
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-568270DOI: 10.1136/jitc-2025-012089ISI: 001564898200001PubMedID: 40866291Scopus ID: 2-s2.0-105014547317OAI: oai:DiVA.org:uu-568270DiVA, id: diva2:2002895
Forskningsfinansiär
Swedish Cancer Society
Merknad

Carina Strell och Patrick Micke delar sistaförfattarskapet

Tilgjengelig fra: 2025-10-02 Laget: 2025-10-02 Sist oppdatert: 2026-04-10bibliografisk kontrollert

Open Access i DiVA

fulltekst(11401 kB)568 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 11401 kBChecksum SHA-512
2e9977101c423ce72bc7ec4ea9d9fe82bc37fb47d5f72d90e7dc223bc76147c114d7b41a461fb3cd803c7690a3fd63ddd602c4611b6b2e6c03aa749db08f73e5
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Yu, HuiAmini, Rose-MarieLindberg, AmandaBackman, MaxMarincevic, MillarayBotling, JohanMattsson, Johanna Sofia MargaretaStrell, CarinaMicke, Patrick

Søk i DiVA

Av forfatter/redaktør
Yu, HuiAmini, Rose-MarieLindberg, AmandaBackman, MaxMarincevic, MillarayBotling, JohanMattsson, Johanna Sofia MargaretaStrell, CarinaMicke, Patrick
Av organisasjonen
I samme tidsskrift
Journal for ImmunoTherapy of Cancer

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 570 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 1045 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf